CHRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Coherus Oncology Inc (CHRS) does not currently present a strong buy opportunity for a beginner investor with a long-term focus. While the stock has potential catalysts in its pipeline and a positive analyst rating, the recent financial performance, lack of significant trading signals, and weak technical indicators suggest a wait-and-see approach is more prudent.
The MACD is slightly positive but contracting, RSI is neutral at 47.497, and moving averages are converging, indicating no clear trend. Key support lies at 1.546, and resistance at 1.798. The stock is trading below its pivot point of 1.672, suggesting bearish sentiment.
Analyst coverage initiated with an Outperform rating and a $10 price target, citing promising clinical readouts in 2026 and high-potential drug candidates.
The stock price dropped by 6.21% during regular market hours and an additional 0.43% post-market. Financial performance shows declining net income (-25.75% YoY) and EPS (-29.55% YoY). No recent news or significant trading trends from hedge funds, insiders, or Congress.
In Q4 2025, revenue grew by 64.85% YoY to $12.75M, but net income declined to -$37.64M (-25.75% YoY), and EPS dropped to -0.31 (-29.55% YoY). Gross margin improved to 68.27%, up 5.94% YoY.
Oppenheimer initiated coverage with an Outperform rating and a $10 price target, citing upcoming clinical readouts and promising drug candidates.
